Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
With so many global regulation changes, staying informed is a challenge. Join other regulatory professionals as you navigate the gray together.
Updated by a group of distinguished regulatory experts, this new edition is a must-have handbook for regulatory professionals at all levels.
In light of the COVID-19 pandemic, the RAC Board has elected to offer online testing with live online proctoring this summer.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 26 May 2016 | By Zachary Brennan
India’s Central Drugs Standards Control Organization (CDSCO) on Thursday released a new draft checklist and evaluation tool for pharmaceutical inspectors of manufacturing sites in India.
The checklist and tool will help CDSCO and state inspectors understand and collaborate on which pharmaceutical and active pharmaceutical ingredient (API) manufacturing sites have been inspected and are compliant.
“The inspections are planned to be carried out jointly by the CDSCO officials and Drug Inspectors of the States concerned. The inspections will assess the compliance of manufacturing facilities with the specified GMP and GLP requirements and also seek to harmonize the procedures for conduct of inspections throughout the country, identify gaps in such compliance and communicate the same to the manufacturers for compliance,” CDSCO said in public notice.
CDSCO also said it will take suggestions and amend the checklist and tool after stakeholders weigh in.
As part of efforts to improve manufacturing quality on the subcontinent, the Indian regulator also initiated a week-long training program on the checklist and evaluation tool, as well as other related areas to ensure the inspections don’t cause “any undue harassment to the manufacturers or their employees and the inspections are carried out in an objective and transparent manner.”
The first of these training programs was conducted between 9 May and 14 May, and the second training program is currently in progress at the National Institute of Biologicals.
Among the items on the checklist are questions on the location and surroundings, building and premises, water and waste system and other pertinent details on warehousing, production, quality control and manufacturing operations and controls.
The notice comes as the US Food and Drug Administration has increasingly been citing Indian manufacturers for data integrity issues dating back to at least 2013, and most recently in April. In some of the most egregious cases, companies have overwritten data collected by software or deleted pertinent data.
Public Notice
GMP Checklist
Tags: Indian drug manufacturing, API manufacturing, data integrity
Regulatory Focus newsletters
All the biggest regulatory news and happenings.